InsidersTradesSigma
Track the ROIVANT SCIENCES LTD stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Market capitalisation: €25.9bn. The latest transaction was reported on 29 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MELISSA EPPERLY. Every trade is free.
Analysts rate ROIVANT SCIENCES LTD Strong Buy (bullish), based on 12 analysts. Average price target: US$39.38.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
ROIVANT SCIENCES LTD is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It employs a technology-driven approach to accelerate drug research and development.